Brenda Leeneman

Brenda Leeneman is an Assistant Professor at the Health Technology Assessment (HTA) department within the Erasmus School of Health Policy & Management at Erasmus University Rotterdam. Her work focuses on economic modeling, clinical outcomes, and treatment evaluation for advanced melanoma therapies.

Her research interests include oncology, health economics, and medical decision-making, particularly in evaluating treatment sequences and cost-effectiveness of immunotherapies like nivolumab. She specializes in modeling melanoma outcomes, hazard ratios, and quality-adjusted life years.

Recent publications address treatment sequencing, economic evaluation of BRAF-mutant melanoma therapies, non-randomized trial methodologies, and long-term survival analysis for advanced melanoma patients. Key subfields include immune checkpoint inhibitors, clinical benefit assessment, and regulatory thresholds.